20 results about "Bacterial host" patented technology

The present disclosure provides engineered bacterial cells having one or more genetic modifications that result in increased production of expression products, such as increased production of plasmids with reduced occurrence of plasmid concatemers or multimers. Also disclosed herein are expression systems for product manufacturing in media having reduced antibiotic concentration, as well as methods of making cells for use in the expression systems. The cells and expression systems increase the growth rate and production yields of biomolecules produced within the host bacterial host cells without the use of antibiotics, and can produce the product with little to no endotoxins present.

The present disclosure concerns a recombinant bacterial host cell capable of providing a nitrogen source to a yeast during fermentation to make ethanol. The recombinant bacterial host cell is capable of converting a biomass into ethanol. The recombinant bacterial host cell has at least one first genetic modification. The at least one genetic modifications confers to the recombinant bacterial host cell the ability to increase, when compared to a corresponding control bacterial cell lacking the at least one first genetic modification, the proteolytic activity associated with the recombinant bacterial host cell. The at least one genetic modification also confers the recombinant bacterial host cell the ability to provide a nitrogen source to a yeast capable of converting the biomass into ethanol, wherein the nitrogen source comprises a peptide, an amino acid and / or ammonia.

DEPCT6604 / 07 / 2566 This invention involves a DNA structure suitable for expression. Recombinant proteins in bacterial host cells that include the following DNA structure: Coding nucleotide sequence: promoter rhaBAD, RhaR transcription activater, RhaS Transcription activators, antibiotic resistance indicators, actively linked promoters. Along with nucleic acids that encode indicators of antibiotic resistance, the terminators rrnBT1 and rrnBT2. The point for initiating self-replication, pMB1, is a DNA structure that may also be assembled with sequences. The nucleotides that encode the recombinant protein are functionally linked to the promoter. This invention, rhaBAD, involves, in addition to a vector and a bacterial host cell that are combined. Given this DNA structure and the method of producing recombinant proteins... By contacting the host bacterial cells with rhamnose, the expression of these cells is stimulated. Of the aforementioned recombinant proteins;

Disclosed are host bacterial strains, methods of making such host bacterial strains and methods of using such host bacterial strains to improve plasmid production. In some embodiments, an engineered bacterial host cell is provided that has a knockout of SbcC, SbcD, or both, and a knockout of one or all of recA, endA, and pgi. In some embodiments, methods for replicating a vector in an engineered E. coli host cell of the present disclosure are provided.

Embodiments of the present disclosure pertain to methods of selecting cyclic peptides that bind to a target by transforming a phage display library with a plurality of nucleic acids into bacterial host cells, where the nucleic acids include phage coat protein genes with a combinatorial region that encodes at least one cysteine and at least one non-canonical amino acid. The transformation results in the production of phage particles with phage coat proteins where the cysteine and the non-canonical amino acid couple to one another to form a cyclic peptide library. Phage particles are then screened against the desired target to select bound cyclic peptides. Amino acid sequences of the selected cyclic peptides are then identified. Additional embodiments pertain to methods of constructing a phage display library that encodes the cyclic peptides. Further embodiments of the present disclosure pertain to the produced cyclic peptides, phage display libraries and phage particles.

The application provides a newly isolated Pseudomonas plecoglossicida phage, a preparation method and application thereof. The phage is preserved in the China Center for Type Culture Collection on February 15, 2023, and the preservation number is CCTCC NO:M 2023124. The application discloses a phage which can efficiently inhibit the growth of Pseudomonas plecoglossicida, and can only infect Pseudomonas plecoglossicida, and has high specificity. The phage can be applied to the fields of agriculture, medicine, environment and the like to resist the bacterial host, and has a good development prospect as an antibiotic substitute.

The present disclosure provides engineered bacterial cells having one or more genetic modifications that result in increased production of expression products, such as increased production of plasmids with reduced occurrence of plasmid concatemers or multimers. Also disclosed herein are expression systems for product manufacturing in media having reduced antibiotic concentration, as well as methods of making cells for use in the expression systems. The cells and expression systems increase the growth rate and production yields of biomolecules produced within the host bacterial host cells without the use of antibiotics, and can produce the product with little to no endotoxins present.

The present disclosure provides modified bacterial cell lysate compositions and methods for cell-free phage synthesis (CFBS) using the compositions to produce a wide range of phage species. Also disclosed herein are bacteriophage engineering methods for converting a lysogenic bacteriophage to a lytic bacteriophage, and methods for producing a genetically modified bacteriophage species that target a wider range of bacterial host strains than a wild type bacteriophage species.

Disclosed are host bacterial strains, methods of making such host bacterial strains and methods of using such host bacterial strains to improve plasmid production. In some embodiments, an engineered bacterial host cell is provided that has a knockout of SbcC, SbcD, or both, and a knockout of one or all of recA, endA, and pgi. In some embodiments, methods for replicating a vector in an engineered E. coli host cell of the present disclosure are provided.

The present disclosure relates to immunogenic polypeptides for eliciting an immune response against influenza. These polypeptides are suitable for use in combination with hemagglutinin (HA)-containing influenza vaccine formulations. Also disclosed are polynucleotides encoding the polypeptides, DNA constructs, recombinant vectors, and recombinant bacterial host cells for expression. The disclosure further provides vaccine compositions comprising the immunogenic polypeptides and pharmaceutically acceptable carriers. Methods for producing the vaccine composition and eliciting an immune response against influenza infection in a subject are also described.

The invention discloses a traceability analysis and multi-habitat homology evaluation method for antibiotic drug-resistant genes in an environmental sample, which is used for cross-habitat transmission and potential source identification of the drug-resistant genes. Comprising the following steps: 1) establishing a multivariate abundance matrix of antibiotic drug-resistant genes in environmental samples, constructing a drug-resistant gene traceability model by utilizing a machine learning algorithm, and accurately predicting potential contribution proportions of different habitats to a target habitat resistance group; and 2) aiming at the identified source habitat, reconstructing a bacterial genome through a genome assembly and binning technology, identifying homologous drug-resistant genes of the source-sink habitat by utilizing multi-sequence alignment and phylogenetic analysis, constructing a multi-medium transmission map of the drug-resistant genes and a transmission network between bacterial hosts, and clarifying connectivity and a transmission mechanism between habitats. According to the method, machine learning traceability and gene homology analysis are integrated, so that systematic evaluation of drug-resistant gene cross-habitat transmission is realized, and technical support is provided for pollution source identification and risk prevention and control of bacterial drug resistance.

The present invention relates to an isolated recombinant polypeptide comprising a fibrinogen gamma chain and a His tag. The present invention also relates to a nucleic acid encoding said polypeptide, a vector comprising said nucleic acid, a host cell, preferably a bacterial host cell, comprising said nucleic acid or vector, a biological hybrid material comprising a conjugate comprising said polypeptide, uses of the above, and a method of manufacturing said polypeptide.

The present invention provides recombinant gram-negative host cells that do not degrade protease-sensitive recombinant proteins yet grow to high cell density, methods for the use of these host cells to produce high-quality recombinant proteins, including antibodies and antibody fragments, at high yield, as well as compositions and methods relating to periplasmic expression of recombinant proteins or polypeptides of interest in host cells.

The present disclosure provides genetically modified Salmonella (GMS) strains with enhanced self-destructing and tumor-navigating activity.

The invention relates to a method for capturing interaction information between bacteria and host cancer cells, in particular to a method for capturing interaction information between the bacteria and the host cancer cells through proximity labeling reaction catalyzed by a metal ruthenium complex and application of the method. In order to solve the problems that an existing common means for researching the interaction between bacteria and host cancer cells is complex in operation and a sample needs to be additionally treated, terpyridyl ruthenium succinimide ester is used as a core catalyst to catalyze an initiated proximity labeling reaction to capture the interaction between the bacteria and the host cancer cells, and the detection method is used for detecting the interaction between the bacteria and the host cancer cells. Furthermore, the strength information of the interaction is detected and analyzed. The method provided by the invention has the characteristic of high efficiency, only marks biomolecules in a direct contact area of bacteria and host cancer cells, and can effectively avoid background interference of non-contact free cells or non-specific adsorption cells. In addition, the method is simple and convenient to operate and does not need additional treatment on the sample. The method is applied to the cross technical field of biochemistry and chemical biology.

The invention provides a process for manufacturing certolizumab pegol from bacterial host cells. The invention provides refolding process of certolizumab wherein the solubilized solution of heavy chain and light chain of certolizumab is treated with refolding buffer under suitable conditions including pII, temperature, and incubation period to obtain high quality and quantity of refolded protein. The invention further provides efficient pegylation process to obtain certolizumab pegol in good yields.

This invention relates to a novel method for the targeting and mapping of phage genes that are essential or important for phage replication in their bacterial host cells, to novel methods for preventing or inhibiting the formation of progeny particles of a phage from a bacterium infected with said phage, and to novel methods for promoting the formation of phage progeny particles from a bacterium.

The present invention relates to methods for the production of oligosaccharides in genetically modified bacterial host cells, as well as to the genetically modified host cells used in the methods. The genetically modified host cell comprises at least one recombinant glycosyltransferase, and at least one nucleic acid sequence coding for a protein enabling the export of the oligosaccharide.

The present invention provides recombinant gram-negative host cells that do not degrade protease-sensitive recombinant proteins yet grow to high cell density, methods for the use of these host cells to produce high-quality recombinant proteins, including antibodies and antibody fragments, at high yield, as well as compositions and methods relating to periplasmic expression of recombinant proteins or polypeptides of interest in host cells.